Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients by Brzović-Šarić, Vlatka et al.
In 2012, more than 371 million people worldwide had 
diabetes. This figure continues to increase, and it is estimated 
that many cases remain undiagnosed [1]. Hyperglycemia-
induced oxidative stress is considered to be a link between 
elevated glucose and other metabolic abnormalities important 
in the development of diabetic complications of neuropathy, 
nephropathy, myocardial injury, and retinopathy [2,3].
Diabetic retinopathy is a serious microvascular compli-
cation that affects the retina, with symptoms appearing late 
after the onset of diabetes. Changes are reflected in the 
structure and function of retinal capillaries, arterioles, and 
venules as a result of pathological processes, such as the 
formation of microvascular obstructions. This causes retinal 
ischemia, neovascularization, and abnormal microvascular 
permeability, which leads to the formation of retinal edema. 
Ultimately, both mechanisms may cause retinal detachment 
and blindness [4-7].
Retinal expression of the angiogenesis inducer vascular 
endothelial growth factor (VEGF) is implicated as a mediator 
of non-proliferative and an initiator of proliferative diabetic 
retinopathies. Oxidative stress mediates the hyperglycemia-
induced pathological effects of VEGF on the microvascular 
complications of diabetes, and increases the permeability 
of the blood-retinal barrier [8]. In experimentally induced 
diabetes, the expression and activity of the antioxidant 
defense system changed along with the transcriptional factors 
and regulatory proteins involved in antioxidant defense 
[9-14]. Analyses of concomitant changes of the oxidative 
stress markers LPO, MDA, SOD, and GSH, as well as other 
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Purpose: In diabetes, an impaired antioxidant defense system contributes to the development of diabetic retinopathy. 
The main objective of this paper was to find correlations of oxidative stress parameters within and between the vitreous 
and serum in patients with type 2 diabetes who had developed proliferative diabetic retinopathy.
Methods: The study included and compared two groups of patients who underwent vitrectomy: 37 patients with type 
2 diabetes and proliferative retinopathy (PDR), and 50 patients with non-diabetic eye disorders (NDED). Vascular en-
dothelial growth factor (VEGF), advanced oxidized protein product (AOPP), and oxidative stress markers (direct lipid 
hydroperoxidation (LPO), malondialdehyde (MDA), total superoxide dismutase (SOD), and glutathione (GSH)) were 
measured in the vitreous and serum of both groups and correlated with one another, between humoral compartments 
and with gender, age, and serum glucose levels.
Results: In the vitreous of PDR patients, VEGF, LPO, and MDA (p<0.05) were increased and SOD values were slightly 
lowered (p<0.05) than in NDED patients. Vitreous AOPP and GSH showed no differences between the groups. In the 
serum, AOPP, MDA, and SOD were increased (p<0.05) and VEGF was slightly increased (p<0.05) in the PDR group 
compared to NDED. With regard to gender, similar changes were recorded for both groups, except for the lower serum 
MDA in males than females in the NDED group. Advanced age showed no significant effect on changes of measured 
parameters in the vitreous. In the serum, VEGF was positively correlated (p<0.05) and MDA and SOD negatively cor-
related (p<0.05) with increasing age. Among measured parameters within and between the vitreous and serum, several 
correlative links occurred in the PDR group that were not present in the NDED group. The most prominent correlation 
changes were between serum LPO and vitreal LPO, serum SOD and vitreal LPO, serum LPO and serum SOD, and 
vitreal VEGF and serum SOD.
Conclusions: Among the selected oxidative stress markers, SOD and LPO were highly correlative in both the vitreous 
and serum in PDR compared to patients without metabolic disorders. Their correlations suggested that monitoring their 
mutual alterations might be informative during PDR development and should be considered in further research.
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markers, such as VEGF or AOPP, can be found in the litera-
ture, individually presented in different studies, assayed by 
different methods on a different number of examined subjects, 
thus preventing the examination of possible correlations and 
ties between all of the assayed parameters in both physiologic 
fluids from the same patients [15-20].
In this study, VEGF, AOPP, LPO, MDA, SOD, and GSH 
were measured in two physiologic media, vitreous and serum, 
in a study group consisting of type 2 diabetes patients with 
developed proliferative diabetic retinopathy (PDR), compared 
to patients without metabolic disorders. The objective of this 
study was to depict concomitant models of change of signifi-
cant high positive or negative physiologic correlations among 
these markers, within and between two physiologic media, 
vitreous and serum, that could be of practical importance for 
further research or monitoring.
METHODS
Participants in the study: The study included two groups of 
patients who underwent vitrectomy during the study period. 
The study group consisted of patients with type 2 diabetes 
with proliferative diabetic retinopathy—the PDR group 
(n=37, average±SD age=68.90±11.65)—and it was compared 
to the second group, which consisted of patients with non-
diabetic eye disorders—the NDED group (n=50, average±SD 
age=61.24±11.94)—having anatomic vitreoretinal disorders 
(macular hole, retinal detachment, epiretinal membrane). 
There were no statistically significant differences between 
mean demographic parameters, age range, or sex of the two 
groups. The diagnosis of type 2 diabetes was based on World 
Health Organization criteria [21], and proliferative diabetic 
retinopathy was classified according to the modified Airlie 
House classification of diabetic retinopathy [22]. All study 
participants were recruited and examined at the Department 
of Ophthalmology, Sveti Duh Clinical Hospital in Zagreb. 
Non-inclusion criteria encompassed subjects previously 
treated with intravitreal steroids or anti-VEGF therapy, 
subjects who had previously undergone vitreoretinal surgery, 
and subjects with other retinal diseases (senile macular 
degeneration, central retinal artery occlusion and/or veins 
and branches), subjects on systemic corticosteroid therapy or 
cytostatics, all subjects with poorly controlled cardiovascular 
status, pregnant women, and women unable to exclude the 
possibility of pregnancy with certainty.
The study was approved by the Ethics Committee of 
the Sveti Duh Clinical Hospital, and was conducted at the 
Department of Ophthalmology of the hospital from June 2012 
to February 2013. All applicable guidelines were followed: 
Basics of Good Clinical Practice, Helsinki Declaration, 
Croatian Healthcare Act, and Patient Rights Act. All patients 
gave their informed consent to participate in the study, after 
receiving detailed information from their ophthalmologist.
Surgical procedure: Vitreous samples (1.5–2.0 ml) were 
obtained by the standard vitreoretinal aspiration procedure, 
pars plana vitrectomy, and all procedures were conducted 
by the same vitreoretinal surgeon. Vitreal samples were 
taken immediately after setting the trocars (before any other 
surgical manipulation) and before turning on the infusion 
system to avoid dilution (filtered air was insufflated to retain 
volume). Samples were centrifuged within one hour after 
surgery for 10 min at 15000 ×g at 4 °C. After centrifuga-
tion, the liquid portion (vitreous) was separated and stored 
at −80 °C until analysis. Blood samples for serum analysis 
(5 ml) were simultaneously collected from the cubital vein, 
in vials containing EDTA, and were centrifuged at 1200 ×g 
at 4 °C. Serum samples were stored at −80 °C. At the time of 
analysis, all samples were dissolved at room temperature and, 
if necessary, centrifuged again. All analyses, sample loading, 
and reagent mixture additions were performed in an array 
manner using equal sample loading by multichannel pipettes.
Chemicals: Chemicals used in the biochemical analysis 
were purchased from Sigma Chemical Company. Bovine 
heart cytochrome C (Type VI) and human blood SOD (Type 
I, lyophilized powder, 2400 U/mg protein), BSA, xantine, 
xantine oxidase, 2-thiobarbituric acid, dodecyl sulfate sodium 
salt, and 1,1,3,3-tetrametoxypropane were purchased from 
Sigma (St. Louis, MO). All other chemicals were of analytical 
grade: OxiSelect™ AOPP Assay Kit, Lipid Hydroperoxide 
Assay kit (Cayman Chemical Company, Ann Arbor, MI), 
VEGF kit (Enzo Life Sciences, Farmingdale, NY), and 
glucose assay kit (GOD-PAP method, HUMAN™).
Glucose assay: Glucose levels in serum were measured 
by a glucose liquicolor (GOD-PAP method) HUMAN™ 
enzymatic colorimetric test for glucose detection following 
the manufacturer’s instructions. Briefly, 1000 µl of reagent 
mixture (glucose oxidase, 4-aminoantipyrinephenol, peroxi-
dase, and mutarotase) was added to 10 µl of the sample. 
Absorbance was measured at 500 nm with a Libro S22 
spectrophotometer (Biochrom, UK). Calculation was made 
by dividing absorbance of the sample by absorbance of a 
supplied glucose standard solution and multiplying by factors 
of 100 and 5.55. The glucose concentration was expressed as 
mmol/l.
VEGF assay: Vascular endothelial growth factor (VEGF) 
was measured using a VEGF ELISA kit (human; Enzo Life 
Sciences, USA). All kit reagents were prepared according 
to the manufacturer’s instructions. A polyclonal antibody 
against human VEGF-16VEGF labeled with the enzyme 
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horseradish peroxidase was added to samples. The measured 
optical density was read at 450 nm and was directly propor-
tional to the concentration of human VEGF in the standards 
or samples. The concentration of VEGF was calculated from 
a calibration curve and expressed as pg/l.
Advanced oxidation protein products (AOPP) assay: AOPP 
was assayed with the OxiSelect™ AOPP Assay Kit according 
to the manufacturer’s instructions. AOPP content was deter-
mined by comparing the test sample with the chloramine stan-
dard curve. Briefly, 200 μl samples or standards were added 
to separate wells of the microtiter plate (Biorad, Hercules, 
CA). A total of 10 μl chloramine reaction initiator was added. 
The absorbance of each well was recorded immediately on a 
spectrophotometric plate reader using a wavelength of 340 
nm. Results were calculated according to a standard curve 
and expressed as µM.
Lipid hydroperoxide (LPO) assay: Lipid hydroperoxide was 
assayed with the Lipid Hydroperoxide Assay kit (Cayman 
Chemical Company) by direct measurement of redox reac-
tion with iron ions according to the kit manual. Briefly, the 
solution LPO Assay Extract R was added to test samples. 
To this mixture, 1 ml cold chloroform solution was added 
and blended. A total of 450 µl of the chloroform-methanol 
mixture was added to 500 µl of extract chloroform sample, 
followed by a 50 µl mixture of chromogen, which turned 
purple. Absorbance was measured at 500 nm with a Spectro 
UVD-3500 spectrophotometer (Labomed Inc., Los Angeles, 
CA). From the calibration curve of LPO, we calculated the 
concentration of LPO in each sample according to the formula 
specified by the manufacturer and expressed as µM.
Malondialdehyde (MDA) assay: The presence of lipid peroxi-
dation was determined by measuring the concentration of 
malondialdehyde (MDA). A total of 200 μl supernatant was 
mixed with 200 μl 8.1% aqueous sodium dodecyl sulfate, 
1.5 ml 20% aqueous acetic acid (pH 3.5), and 1.5 ml 0.81% 
aqueous thiobarbituric acid and heated for 60 min at 95 °C. 
After cooling samples on ice, absorbance was measured at 
532 nm and 600 nm with a Libro S22 spectrophotometer 
(Biochrom, Cambridge, UK). The total absorbance was 
determined using the formula Atotal=A532 - A600. An array of 
known concentrations of tetramethoxypropane was used for 
creating the calibration curve using the same protocol as for 
the homogenized samples. MDA values are presented as 
nmol/mL.
Glutathione assay (GSH) assay: The glutathione assay is a 
modification of the method first described by Tietze [23]. 
Briefly, in a 96-well plate, 40 μl 10 mM 5–5′-dithiobis 
[2-nitrobenzoic acid] (DTNB, Ellman’s Reagent) was added 
to 20 μl sample supernatant pre-treated with 40 µl 0.035M 
HCL. This mixture was incubated for 10 min. DTNB reacts 
with GSH to form chromospheres. The absorbance of these 
chromogens was measured at 412 nm in an ELISA plate 
reader (BIORAD). Then, 100 µl reaction mixture (9980 µl 
0.8 mM NADPH and 20 µl gluthatione reductase, 0.2 U/
ml) was added and the absorbance was read at 412 nm every 
minute for 5 min. The results were calculated from the 
standard curve of array of dilutions of glutathione (GSH). 
Concentrations are presented as µmol/ml.
Total superoxide dismutase (SOD) assay: The measure of 
SOD activity is calculated from the percentage of inhibi-
tion of the reaction of xantine oxidation by xantine oxidase 
(optimized reaction ratio ΔA/ min≈0.025), which creates a 
superoxide anion as a substrate for SOD. The superoxide 
anion not used by the enzyme SOD oxidizes the cytochrome. 
For determination of SOD activity, 25 µl of undiluted sample 
were mixed with 1.45 ml of the reaction mix (cytochrome C, 
0.05 mM; xantine, 1 mM mixed to a 10:1 ratio with addition 
of DTNB). To this mixture, 20 µl xantine oxidase 0.4 Uml−1 
was added to start a reaction. The reaction was measured over 
3 min at 550 nm. The absorbance and percentage of inhibition 
were compared to the calibration curve created with different 
dilutions of SOD. Enzyme values are presented as U/ml.
Statistical analysis: Statistics were based on non-parametric 
methods, due to the small sample size and non-normal data 
distribution (verified by the Kolmogorov–Smirnov test). The 
Mann–Whitney U test was used to analyze numerical vari-
ables between groups. Spearman’s rank correlation was used 
for correlation analysis within and between measured param-
eters in the vitreous and serum of both groups of patients 
(NDED and PDR). Analyses were performed using SPSS 
version 17 (SPSS Inc., Chicago, IL). The level of statistical 
significance was set at p≤0.05.
RESULTS
A comparison of gender-dependent differences (Table 1) 
revealed that there were no statistically significant gender 
differences in the measured parameters in the vitreous or 
serum, except a single detected difference in the NDED 
group, where serum MDA was significantly lower (p≤0.05) 
in male than in female patients. However, within the same 
gender groups, there were significant differences (p≤0.05) 
between the NDED and PDR groups in the majority of 
measured parameters (Table 1).
Trends of statistical differences in the measured param-
eters between the NDED and PDR groups by age distribution 
(Table 2) were similar to trends within the sexes (Table 1). The 
correlation of the measured parameters and age of patients 
included in the study (Table 2) revealed a significant negative 
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correlation (p≤0.05) of serum MDA and SOD activity with 
increased age in PDR patients, and serum VEGF was posi-
tively correlated with increasing age.
The analysis of serum glucose of NDED patients and 
PDR patients at the time of the procedure (Figure 1) revealed 
that glucose levels were as expected, i.e., were significantly 
higher (p≤0.05) in PDR patients than in NDED patients. 
However, serum glucose values did not correlate significantly 
with changes of the measured parameters in either group 
(Table 3), with the exception of a slight significant positive 
correlation with MDA in the NDED group.
Vitreous VEGF levels were significantly increased 
(p≤0.05), almost 10-fold, in the PDR group compared to 
NDED patients (Figure 2). Serum VEGF of the PDR group 
was also increased significantly (p≤0.05; Figure 2). However, 
since the scale on Figure 2 is set for vitreal VEGF, the serum 
VEGF range is provided here (serum VEGF: NDED range 
2.0–104 pg/ml; PDR range 5.0–760 pg/ml).
The analysis of advanced oxidized protein product 
(AOPP) levels (Figure 3) revealed no statistical differences 
between NDED and PDR patients. Serum AOPP levels in 
NDED patients were only slightly significantly (p≤0.05) 
higher than in the vitreous. However, serum AOPP levels 
were significantly higher (p≤0.05) in PDR than in NDED 
patients.
Lipid peroxidation (LPO; Figure 4) was almost equal in 
the vitreous and serum in the NDED group. In the PDR group, 
LPO values were slightly but significantly higher (p≤0.05) in 
serum than in the vitreous. In a comparison between groups, 
LPO values were significantly (p≤0.05) higher in the PDR 
group, with an almost five-fold increase of the peroxydized 
lipid concentration. The LPO analysis marked the most prom-
inent change of all the analyzed oxidative stress markers.
Similarly, MDA (Figure 5) is also a lipid peroxidation 
marker. It was established that serum levels were higher 
(p≤0.05) than vitreous values in the PDR group. In the NDED 
group, serum and vitreous MDA values showed no significant 
difference. However, vitreous and serum MDA values were 
significantly higher (p≤0.05) in the PDR than in the NDED 
group.
The activity of total superoxide dismutase (SOD; Figure 
6) was slightly but significantly (p≤0.05) lower in serum than 
in the vitreous of the NDED subjects. In PDR patients, the 
vitreal SOD activity was slightly but significantly (p≤0.05) 
lower than in NDED patients, while serum SOD activity was 
significantly higher (p≤0.05) compared to NDED patients.
Glutathione levels (GSH) were significantly (p≤0.05) 
higher in the serum than in the vitreous of both NDED 
and PDR groups; however, no significant differences were 
detected in the serum or vitreous GSH levels between the 
groups (Figure 7).
Table 1. Measured paraMeTers and sTaTisTical differences wiThin and beTween genders in non-diabeTic 
paTienTs wiTh eye disorders (nded) and proliferaTive diabeTic reTinopaThy (pdr) paTienTs.
Parameter Group
Vitreous Serum
Male Female Male Female
Mean ±S.E Mean ±S.E Mean ±S.E Mean ±S.E
VEGF (pg/l) NDED 176.3±34.8 213.5±50.5 18.9±2.7 29.0±6.2
 PDR 2048.9±408.4* 1127.2±23.6* 70.7±26.7* 50.0±16.8
AOPP(µM) NDED 44.0±12.3 43.9±25.6 231.9±19.6 250.3±18.8
 PDR 68.6±19.0 51.4±20.6 379.4±46.8* 522.1±134.1*
LPO (µM) NDED 27.0±2.4 33.0±4.9 26.2±2.3 26.2±1.5
 PDR 145.8±6.3* 135.6±10.9* 168.1±6.9* 159.0±8.7*
MDA (nmol/ml) NDED 55.8±10.9 58.1±12.5 31.9±3.1 40.4±6.4#
 PDR 101.3±7.6* 87.6±18.4* 151.5±12.5* 156.2±25.7*
SOD (U/ml) NDED 76.3±11.9 50.5±7.2 24.3±1.3 26.7±2.0
 PDR 30.5±2.5* 28.5±3.8* 158.8±23.5* 122.1±13.7*
GSH (µmol/ml) NDED 41.1±1.1 38.9±0.4 90.5±6.32 80.2±5.4
 PDR 43.7±1.8 48.8±5.8 73.5±2.9* 69.9±5.7*
* values are statistically different (p≤0.05) from the same parameter of non-diabetic patients with eye disorders (NDED) within the same 
gender group (column), i.e., males in NDED versus PDR; females in NDED versus PDR. # values are statistically different between 
genders within non-diabetic patients with eye disorders (NDED) and with proliferative diabetic retinopathy (PDR) patients (p≤0.05).
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The Spearman correlation coefficients of the measured 
parameters in the NDED subjects are presented in Table 4 
and for PDR patients in Table 5. In the NDED group, the 
only significant correlation between the measured parameters 
was the negative correlation between GSH and SOD in serum 
(Table 4, ρ=-0.627; p<0.001). In PDR, however, several corre-
lations occurred as a consequence of the pathological condi-
tion and new allostasis (Table 5). The significantly (p≤0.05) 
strongest ones (ρ ≤ ±0.600) were between vitreous LPO and 
serum SOD (Table 5, Figure 8A), serum SOD and LPO (Table 
5, Figure 8B), vitreous LPO and serum LPO (Table 5, Figure 
8C), and vitreous VEGF and serum SOD (Table 5, Figure 
8D).
DISCUSSION
Investigating the dynamics and correlative ties of oxidative 
stress markers in homeostatically linked physiologic fluids, 
i.e., the vitreous and serum of patients having proliferative 
diabetic retinopathy (PDR), might reveal possible markers and 
their ratios for disease control and monitoring progression.
This study of the links and correlations between the 
measured parameters indicated that all parameters assayed in 
the serum or eye of NDED subjects had ρ (Spearman correla-
tion coefficient) values near zero. Conclusively, markers in 
the vitreous or serum were physiologically independent in the 
NDED group (Table 4). Conversely, in PDR patients, diabetic 
retinopathy and increased oxidative stress resulted in several 
statistically significant correlations between the measured 
parameters in the vitreous and serum (Table 5). This is likely 
due to the fact that the blood-retinal barrier becomes more 
permeable in diabetes, as has been shown experimentally [8].
Age (Table 2) was found to be a partially contributing 
factor, i.e., with increasing age of diabetic patients, there was 
a significant increase of serum VEGF and a reduction of 
serum SOD and MDA, but age did not influence the vitreal 
changes. One must remember that the overall serum SOD 
activity and MDA levels were 3–4 times higher in PDR than 
in NDED patients, and the correlation with age occurs in such 
a higher range of pathophysiological allostasis (Figure 5 and 
Figure 6).
The analysis of glucose levels (Figure 1) shows that, at 
the time of analysis in diabetic patients (fasting patients on 
the day of operation), it may be statistically but is not promi-
nently higher. Parameters were not significantly correlated to 
glucose levels at the time of measurement (Table 3). Rather, 
it is the long period of fluctuations of all biochemical param-
eters over time that results in the imbalance of the antioxidant 
defense system.
VEGF was found to be increased in the vitreous of 
PDR patients (Figure 2), similar to [24-26]. However, in this 
study, a moderate yet significant positive correlation (ρ=0.357 
Figure 1. Average serum glucose 
concentrations in non-diabetic 
pat ients with eye disorders 
(NDED) and proliferative diabetic 
retinopathy (PDR) patients. NDED 
group (n=50); PDR group (n=37). 
aColumns are significantly different 
(p≤0.05).
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Table 3. correlaTion of Measured paraMeTers wiTh seruM glucose in non-diabeTic paTienTs 
wiTh eye disorders (nded) and proliferaTive diabeTic reTinopaThy (pdr) paTienTs.
Parameter Group
Serum glucose
Vitreous Serum
Spearman coeffi-
cient of correlation 
(ρ)
p
Spearman coeffi-
cient of correlation 
(ρ)
p
AGE (years) NDED / / 0.078 0.695
 PDR / / −0.217 0.257
VEGF (pg/l) NDED −0.006 0.968 −0.143 0.357
 PDR 0.249 0.155 −0.133 0.452
AOPP (µM) NDED −0.172 0.381 0.225 0.240
 PDR −0.098 0.580 0.018 0.917
LPO (µM) NDED 0.100 0.512 0.257 0.088
 PDR −0.076 0.666 −0.099 0.5767
MDA (nmol/ml) NDED 0.132 0.517 0.302# 0.045
 PDR 0.149 0.529 0.207 0.262
SOD (U/ml) NDED 0.184 0.253 −0.046 0.774
 PDR −0.101 0.592 0.071 0.729
GSH (µmol/ml) NDED −0.246 0.111 −0.115 0.467
 PDR 0.133 0.466 0.315 0.116
#values are statistically significantly correlated (p≤0.05) with glucose within the non-diabetic patients with eye disorders (NDED) or 
proliferative diabetic retinopathy (PDR) group. ρ - Spearman correlation analysis coefficient; p- level of statistical significance (p≤0.05) 
of Spearman correlation analysis.
Figure 2. Relationships of vitreous 
and serum VEGF values in non-
diabetic patients with eye disorders 
(NDED) and proliferative diabetic 
retinopathy (PDR) patients. NDED 
group (n=50); PDR group (n=37). 
aBoxes are significantly different 
(p≤0.05).
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Figure 3. Relationships of vitreous 
and serum AOPP values in non-
diabetic patients with eye disorders 
(NDED) and proliferative diabetic 
ret inopathy (PDR) pat ients. 
NDED group (n=50); PDR group 
(n=37). a,b,cBoxes bearing the same 
superscript letter are significantly 
different (p≤0.05).
Figure 4. Relationships of vitreous 
and serum LPO values in non-
diabetic patients with eye disorders 
(NDED) and proliferative diabetic 
ret inopathy (PDR) pat ients. 
NDED group (n=50); PDR group 
(n=37). a,b,cBoxes bearing the same 
superscript letter are significantly 
different (p≤0.05).
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Figure 5. Relationships of vitreous 
and serum MDA values in non-
diabetic patients with eye disorders 
(NDED) and proliferative diabetic 
ret inopathy (PDR) pat ients. 
NDED group (n=50); PDR group 
(n=37). a,b,cBoxes bearing the same 
superscript letter are significantly 
different (p≤0.05).
Figure 6. Relationships of vitreous 
and serum SOD activity levels 
in non-diabetic patients with eye 
disorders (NDED) and proliferative 
diabetic retinopathy (PDR) patients. 
NDED group (n=50); PDR group 
(n=37). a,b,c,dBoxes bearing the same 
superscript letter are significantly 
different (p≤0.05).
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and p=0.001; Table 5) was found between the vitreous and 
serum VEGF in the PDR group. We note that, in diabetes, 
microvascularization in other tissues also contribute to an 
increase in serum VEGF, though this significant correlation 
between serum and vitreous levels may suggest an important 
physiologic link between these humoral compartments [8]. As 
such, serum levels could perhaps reflect intraocular changes.
AOPPs are structurally similar to advanced glycation 
end-product (AGE) and exert similar biologic activity. Serum 
AOPP levels are elevated in patients with renal complications, 
atherosclerosis, and diabetes [27]. The present study revealed 
no statistically significant differences in vitreous AOPP 
between the NDED and PDR patients (Figure 1). The estab-
lished difference between higher serum than vitreal values of 
AOPP can be explained by the higher protein content in serum 
than in the vitreous, and higher values of serum oxidized 
proteins in PDR than in NDED patients. Data on AOPP 
levels in the vitreous of diabetic patients with PDR disease is 
scarce, though serum AOPP increases in diabetes have been 
reported, together with an increase in oxidized albumin and 
protein carbonyls [27-31]. The correlation analysis showed 
that AOPP increased independently from other parameters, 
since it was not significantly correlated to changes in other 
parameters in either the vitreous or serum. Accordingly, the 
AOPP method used here does not reflect vitreous oxidative 
stress and is more specific for plasmatic oxidative stress 
products. Glutathione (GSH), a small peptide, showed no 
prominent changes. There are reports of unchanged thiol 
levels in PDR patients [27]. Others, however, have reported 
total thiol levels and GSH depletion in serum and vitreous in 
human subjects with PDR [32], though most of the reports are 
on animal models [33-35].
The results and comparison of lipid peroxidation markers 
using direct measures of lipid peroxidation (LPO) and indi-
rect measures of the lipid peroxidation byproduct malondial-
dehide (MDA) indicated that the LPO measurement method 
(Figure 4) showed a more prominent difference (5–7 times 
higher increase in serum and vitreous) than the MDA method 
(2–3 times increase in serum and vitreous) in the PDR group 
(Figure 5). There are no literature reports assessing lipid 
peroxidation (LPO) using the method described here, though 
earlier studies measuring lipid peroxidation using other 
markers yielded significantly increased results [35]. The 
present results on MDA changes in the vitreous of diabetic 
patients with PDR are in accordance with the studies by 
Mandal et al. [36] and Manciano et al. [37], which showed 
an increase in vitreal MDA in PDR patients. They also indi-
cated that lipid peroxidation in diabetic patients with PDR 
is a highly pronounced process in the humoral parts of the 
organism, and lipid peroxidation appears to be highly respon-
sible for induced oxidative stress in diabetic patients [38,39]. 
The LPO method is more sensitive compared to methods that 
measure lipid peroxidation byproducts, such as MDA. LPO 
offers a better picture of the extent of lipid peroxidation than 
Figure 7. Relationships of vitreous 
and serum GSH values in non-
diabetic patients with eye disorders 
(NDED) and proliferative diabetic 
retinopathy (PDR) patients. NDED 
group (n=50); PDR group (n=37). 
a,b,c,dBoxes bear ing the same 
superscript letter are significantly 
different (p≤0.05).
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MDA. This was confirmed by the significant correlations 
between LPO in the vitreous and serum. MDA was the only 
serum variable in the study group to remain independent 
from the other parameters. Its ρ value remained similar as 
in the NDED group. This indicates that the MDA change 
in serum does not reflect changes in the vitreous but rather 
depends on systemic sources from other tissues. In addition, 
the determined ρ value for LPO showed a significant positive 
association with increased LPO concentrations in the eye and 
in serum, but also with vitreous MDA and SOD and serum 
VEGF, AOPP, SOD, and especially with serum LPO. These 
results indicate that the increase in overall serum LPO levels, 
compared to normal serum levels, is approximately twice the 
increase in lipid peroxidation in the eye. Given that previous 
studies [35,39] have shown a significant correlation between 
the increase of LPO in the vitreous and an increase in the 
expression of vascular endothelial growth factors (VEGF), 
it appears that LPO determination in serum might be a good 
predictor for the onset of oxidative stress within the vitreous. 
Furthermore, Table 5 and Figure 8 show that a pronounced 
correlation change was found for serum LPO and serum SOD 
activity. A relatively strong and physiologically significant 
correlation was recorded between serum SOD activity and 
vitreous LPO levels. Unlike the high serum SOD activity, the 
ocular activity of SOD shown in Figure 6 is likely to decrease 
slightly compared to NDED patients. Yildirim et al. [17] 
reported no changes in serum SOD activity in PDR patients. 
This can be explained by the saturation of the ocular enzyme 
by its substrate (superoxide radical), which is a free radical 
whose concentration is elevated during oxidative stress. On 
the other hand, SOD activity was positively correlated with 
vitreous VEGF [40].
SOD activity could be important in diabetics with PDR, 
as indicated elsewhere [40-44]. This study shows that it can 
be monitored with LPO, as they concomitantly change in both 
the eye and in serum. For the exact dynamics of oxidative 
markers and serum-vitreous relations, a multi-year study 
would be required on the same diabetic patients from early 
diabetes onset to late retinopathy changes. Nevertheless, 
studies of the final proliferative state offer reliable initial 
Figure 8. The strongest correlations between the measured markers in non-diabetic patients with eye disorders (NDED) and proliferative 
diabetic retinopathy (PDR) patients; A) LPO vitreous and SOD serum, B) LPO serum and SOD serum, C) LPO vitreous and LPO serum, 
D) VEGF vitreous and SOD serum.
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findings of candidate markers [26,40,45]. Based on the results 
of this study, it can be concluded that further research on 
concomitant changes and ratios of vitreal and serum LPO 
and SOD activity could be promising as possible indicators 
of oxidative change in the eye, if performed alongside other 
linked ratios [41,45]. These conclusions are supported by the 
significant correlations reported in this study. The correla-
tions suggest that monitoring their mutual alterations might 
be informative during PDR development and should be taken 
into consideration in further research, including animal 
studies and human studies of diabetic retinopathy develop-
ment in asymptomatic patients with no clinical signs.
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